drugset / Trial / NCT06691906

A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)

NCT06691906

Phase 1 Completed 40 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to learn what happens to the amount of enlicitide decanoate in the blood when enlicitide decanoate is given in different formulations.

Timeline

Start
2024-03-18
Primary completion
2024-05-01
Completion
2024-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Enlicitide Decanoate Unknown Oral

Indications

No indication recorded.